Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Gamerith G, Kocher F, Rudzki J, et al. ASCO 2018 NSCLC highlights-combination therapy is key. Memo. 2018;11(4):266–271.
   PubMedGoogle Scholar
• Chowell D, Morris LGT, Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582–587.
   PubMed Web of Science ®Google Scholar
• Yamada A, Sasada T, Noguchi M, et al. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104(1):15–21.
   PubMed Web of Science ®Google Scholar
• Sasada T, Yamada A, Noguchi M, et al. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem. 2014;21(21):2332–2345.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Noguchi M, Yamada A, et al. Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther. 2016;16(5):689–698.
   PubMed Web of Science ®Google Scholar
• Yoshiyama K, Terazaki Y, Matsueda S, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cell lung cancer. Int J Oncol. 2012;40(5):1492–1500.
   PubMed Web of Science ®Google Scholar
• Yamada T, Terazaki Y, Sakamoto S, et al. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens. Int J Oncol. 2015;46(1):55–62.
   PubMed Web of Science ®Google Scholar
• Takayama K, Sugawara S, Saijo Y, et al. Randomized Phase II study of docetaxel plus personalized peptide vaccination versus docetaxel plus placebo for patients with previously treated advanced wild type EGFR non-small-cell lung cancer. J Immunol Res. 2016;2016:1745108.
   PubMed Web of Science ®Google Scholar
• Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062–1069.
   PubMed Web of Science ®Google Scholar
• Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4(2):139–163.
   PubMed Web of Science ®Google Scholar
• Giacona MB, Ruben GC, Iczkowski KA, et al. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas. 1998;17(1):89–97.
   PubMed Web of Science ®Google Scholar
• Cheng J, Tang Q, Cao X, et al. Cell-free circulating DNA integrity based on peripheral blood as a biomarker for diagnosis of cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2017;26(11):1595–1602.
   PubMed Web of Science ®Google Scholar
• Zhang R, Pu W, Zhang S, et al. Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: a retrospective cohort trial. PLoS One. 2018;13(2):e0191756.
   PubMed Web of Science ®Google Scholar
• Soliman SE, Alhanafy AM, Habib MSE, et al. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non-small cell lung cancer. Biochem Biophys Rep. 2018;15:45–51.
   PubMedGoogle Scholar
• Chudasama DY, Aladag Z, Felicien MI, et al. Prognostic value of the DNA integrity index in patients with malignant lung tumors. Oncotarget. 2018;9(30):21281–21288.
   PubMedGoogle Scholar
• Kitahara M, Hazama S, Tsunedomi R, et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci. 2016;107(12):1825–1829.
   PubMed Web of Science ®Google Scholar
• Waki K, Yokomizo K, Kawano K, et al. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients . Cancer Immunol Immunother. 2020; 69(10):2001–2007.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Lawrence M, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214–218.
   PubMed Web of Science ®Google Scholar
• Huang Z, Su W, Lu T, et al. First-line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress. Front Pharmacol. 2020;11:578091.
   PubMed Web of Science ®Google Scholar
• Palaia I, Tomao F, Sassu CM, et al. Immunotherapy for ovarian cancer: recent advances and combination therapeutic approaches. Onco Targets Ther. 2020;13:6109–6129.
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mine T, Komatsu N, et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 2010;10(12):1266–1279.
   PubMed Web of Science ®Google Scholar
• Shirahama T, Muroya D, Matsueda S, et al. A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer Sci. 2017;108(5):838–845.
   PubMed Web of Science ®Google Scholar
• Kibe S, Yutani S, Motoyama S, et al. Phase II study of personalized peptide vaccination for previously treated advanced colorectal cancer. Cancer Immunol Res. 2014;2(12):1154–1162.
   PubMed Web of Science ®Google Scholar
• Yutani S, Komatsu N, Yoshitomi M, et al. A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. Oncol Rep. 2013;30(3):1094–1100.
   PubMed Web of Science ®Google Scholar
• Yoshitomi M, Yutani S, Matsueda S, et al. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis. Exp Ther Med. 2012;3(3):463–469.
   PubMed Web of Science ®Google Scholar
• Waki K, Kawano K, Tsuda N, et al. Plasma levels of high-mobility group box 1 during peptide vaccination in patients with recurrent ovarian cancer. J Immunol Res. 2017;2017:1423683.
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56.
   PubMed Web of Science ®Google Scholar